Liisa Bayko

Number of patients with bronchiectasis, this is in the U.S., those with a CT scan, how many are under care and then how many have at least two exacerbations

do you anticipate any requirements for, say, reauthorization or continued treatment would be based on certain markers of drug response

how many of those patients were kind of fully paying patients? What are gross to nets? And how do you anticipate that evolving as the year goes on

Can you maybe describe sort of any, like stocking? It seems like you are trying to get product available in the different channels

where it falls in line in the ambulatory care setting if the onset of action is a little bit longer